维得利珠单抗不增加恶性肿瘤发生率:GEMINI长期安全性研究及上市后数据
基于GEMINI长期安全性研究(1785例,5670患者年)及上市后安全性数据库,维得利珠单抗治疗中观察到的恶性肿瘤数与IBD人群预期值相似(31 vs 29,比值1.08,P=0.71,95%CI 0.73-1.53)。
要点
- 维得利珠单抗治疗者恶性肿瘤观察数与IBD预期数无统计学差异。
- 长期安全性研究中位随访≥1年,最常见为肾及膀胱恶性肿瘤(6例)。
- 上市后数据中下消化道恶性肿瘤最常见(59例),总体数量看似较低。
核心结论
- GEMINI长期安全性研究中维得利珠单抗治疗者的恶性肿瘤发生数与无统计学显著差异的IBD预期数相似。
- 上市后安全性数据库显示维得利珠单抗相关恶性肿瘤数量看似较低,但需考虑自发报告局限性。
研究设计与样本
- GEMINI长期安全性研究(2009年5月至2018年5月)纳入1785例有≥1年随访的患者,共5670患者年。
- 长期安全性研究采用间接标准化法,以Optum CDM数据库中IBD患者年龄和性别特异恶性肿瘤发生率计算预期数。
主要发现
- 长期安全性研究中观察到的恶性肿瘤为31例,预期为29例,观察/预期比值=1.08(P=0.71,95%CI 0.73-1.53)。
- 长期安全性研究中最常见恶性肿瘤为肾及膀胱癌(6例)。
- 上市后数据库中293例患者报告299例恶性肿瘤(包括维得利珠单抗起始后1年内的恶性肿瘤),下消化道恶性肿瘤最常见(59例)。
关键数值与推荐
- 长期安全性研究排除维得利珠单抗起始后1年内发生的恶性肿瘤。
- 恶性肿瘤识别采用MedDRA编码。
临床怎么用
- 对于中重度克罗恩病和溃疡性结肠炎患者,维得利珠单抗治疗未显示增加恶性肿瘤风险。
- 临床决策时仍需结合患者个体情况,尤其是有恶性肿瘤病史或高危因素者。
局限性
- 长期安全性研究仅能校正少量混杂因素。
- 上市后安全性报告存在报告不足等局限性,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vedolizumab is a gut-selective antibody to α4 β7 integrin approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of malignancy. AIM: To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI long-term safety (LTS) study and post-marketing (PM) setting. METHODS: Malignancy data from the LTS study (May 2009 to May 2018), and data from the vedolizumab Global Safety Database (20 May 2014 to 19 May 2018), were identified using Medical Dictionary for Regulatory Activities coding. The number of patients experiencing malignancies in the LTS study (excluding malignancies within 1 year following vedolizumab initiation) was indirectly standardised against the number expected, using age- and sex-specific rates in patients with IBD from Optum's Clinformatics™ Data Mart (CDM) database. RESULTS: Among 1785 patients with ≥1 year of follow-up post-vedolizumab initiation in the LTS study (total 5670 patient-years), observed numbers of malignancies were similar to those expected compared with CDM data (31 vs 29; ratio of observed to expected events = 1.08; P = 0.71; 95% confidence intervals [CI] 0.73, 1.53). The most common malignancies were renal and bladder (6). PM, 293 patients reported 299 malignancies (including malignancies within 1 year following vedolizumab initiation), in approximately 208 050 patient-years of vedolizumab exposure. Lower gastrointestinal malignancies were most common (59). CONCLUSIONS: The number of malignancies in the LTS study was similar to that expected from an IBD population with no statistically significant differences, although few confounders could be corrected for. Limitations of PM safety reporting require consideration; however, the number of malignancies with vedolizumab appeared low.
引用
- Card T, Ungaro R, Bhayat F, et al. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther. 2019. PMID: 31747086. doi:10.1111/apt.15538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。